NOD2 and tuberculosis: We further demonstrate that Inarigivir boosts the efficacy of the BCG vaccine against tuberculosis in mice and represents a new generation of adjuvants that target NOD2/RIG-I signaling and perhaps they can be safely combined with other vaccines.